<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02951182</url>
  </required_header>
  <id_info>
    <org_study_id>VX15-440-101</org_study_id>
    <secondary_id>2016-000454-36</secondary_id>
    <nct_id>NCT02951182</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis</brief_title>
  <official_title>A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-440 Combination Therapy in Subjects Aged 12 Years and Older With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, randomized, double-blind, placebo- and active-controlled, parallel group,
      multicenter study to evaluate the safety, tolerability, and efficacy of VX-440 in dual and
      triple combination with tezacaftor (TEZ; VX-661) and ivacaftor (IVA; VX-770) in subjects with
      cystic fibrosis (CF) who are homozygous for the F508del mutation of the CF transmembrane
      conductance regulator (CFTR) gene (F508del/F508del), or who are heterozygous for the F508del
      mutation and a minimal function (MF) CFTR mutation not likely to respond to TEZ and/or IVA
      therapy (F508del/MF).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability as assessed by number of subjects with adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>from baseline up to 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Absolute change in percent predicted forced expiratory volume in 1 second (ppFEV1)</measure>
    <time_frame>from baseline up to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in sweat chloride concentrations</measure>
    <time_frame>from baseline up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change in ppFEV1</measure>
    <time_frame>from baseline up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of pulmonary exacerbations</measure>
    <time_frame>through Week 12 (12-week cohort only)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first pulmonary exacerbation</measure>
    <time_frame>through Week 12 (12-week cohort only)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in body mass index (BMI)</measure>
    <time_frame>from baseline at Week 12 (12-week cohort only)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in BMI z-score</measure>
    <time_frame>from baseline at Week 12 (12-week cohort only)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in weight</measure>
    <time_frame>from baseline at Week 12 (12-week cohort only)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain score</measure>
    <time_frame>from baseline up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) of VX-440, TEZ, M1-TEZ, IVA, and M1-IVA (μg/mL)</measure>
    <time_frame>from Day 1 through Day 43 (4-week cohorts), and through Week 12 (12-week cohort)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve during a dosing interval (AUCtau) of VX-440, TEZ, M1-TEZ, IVA, and M1-IVA (μg.h/mL)</measure>
    <time_frame>from Day 1 through Day 43 (4-week cohorts), and through Week 12 (12-week cohort)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed pre-dose concentration (Ctrough) of VX-440, TEZ, M1-TEZ, IVA, and M1-IVA (μg/mL)</measure>
    <time_frame>from Day 1 through Day 43 (4-week cohorts), and through Week 12 (12-week cohort)</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort A:Triple Combination(TC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VX-440 200 milligram (mg) administered every 12 hours (q12h). TEZ 100 mg administered once daily (qd). IVA 150 mg q12h.
Morning Dose: VX-440 + TEZ/IVA
Evening Dose: VX-440 + IVA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort A: Triple Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebos matched to VX-440, TEZ/IVA, and IVA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort B TC-High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To be initiated after blinded review of Cohort A, if supported by safety and PK Data.
The dosage of VX-440 may be adjusted based on data from Cohort A.
Morning Dose: VX-440 + TEZ + IVA
Evening Dose: VX-440 + TEZ + IVA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort B:TC-Low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To be initiated after blinded review of Cohort A, if supported by safety and PK Data.
Placebo matched to VX-440
Morning Dose: VX-440 + TEZ + IVA
Evening Dose: VX-440 + TEZ + IVA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterozygous F508del/MF 4- week Cohort B: Triple Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>To be initiated after blinded review of Cohort A, if supported by safety and PK Data.
Placebos matched to VX-440, TEZ, and IVA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Homozygous F508del/F508del 4-week Cohort: TC- High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To be initiated after the Cohort A blinded review, if supported by safety and PK data.
The dosage of VX-440 may be adjusted based on data from Cohort A.
Placebo matched to morning TEZ/IVA.
Morning Dose: VX-440 + TEZ + IVA
Evening Dose: VX-440 + TEZ + IVA
The treatment period will be preceded by a 4-week run-in period and followed by a 4-week washout period, during both of which subjects will receive:
TEZ 100 mg administered once daily (qd). IVA 150 mg q12h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Homozygous F508del/F508del 4-week Cohort: TEZ/IVA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>To be initiated after blinded review of Cohort A, if supported by safety and PK Data.
Placebos matched to VX-440, evening TEZ, and morning IVA.
TEZ 100 mg administered once daily (qd). IVA 150 mg q12h.
Morning Dose: TEZ/IVA
Evening Dose: IVA
The treatment period will be preceded by a 4-week run-in period and followed by a 4-week washout period, during both of which subjects will receive:
TEZ 100 mg administered once daily (qd). IVA 150 mg q12h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: TC-High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To be initiated after blinded review of Cohorts A and B, if supported by safety, PK, and efficacy data.
The dosage of VX-440 will be determined based on data from Heterozygous F508del/MF 4-week Cohorts A and B.
Morning Dose: VX-440 + TEZ + IVA
Evening Dose: VX-440 + TEZ + IVA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: TC-Low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To be initiated after blinded review of Cohorts A and B, if supported by safety, PK, and efficacy data.
The dosage of VX-440 will be determined based on data from Heterozygous F508del/MF 4-week Cohorts A and B.
Placebo matched to VX-440
Morning Dose: VX-440 + TEZ + IVA
Evening Dose: VX-440 + TEZ + IVA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: Dual IVA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To be initiated after blinded review of Cohorts A and B, if supported by safety, PK, and efficacy data.
The dosage of VX-440 will be determined based on data from Heterozygous F508del/MF 4-week Cohorts A and B.
Placebo matched to TEZ.
Morning Dose: VX-440 + IVA
Evening Dose: VX-440 + IVA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: Dual TEZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To be initiated after blinded review of Cohorts A and B, if supported by safety, PK, and efficacy data.
The dosage of VX-440 will be determined based on data from Heterozygous F508del/MF 4-week Cohorts A and B.
Placebo matched to IVA
Morning Dose: VX-440 + TEZ
Evening Dose: VX-440 + TEZ
VX-440 administered in combination with TEZ q12h and placebo matched IVA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: Triple Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>To be initiated after blinded review of Cohorts A and B, if supported by safety, PK, and efficacy data.
Placebos matched to VX-440, TEZ, and IVA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tezacaftor</intervention_name>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort A:Triple Combination(TC)</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort B TC-High</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort B:TC-Low</arm_group_label>
    <arm_group_label>Homozygous F508del/F508del 4-week Cohort: TC- High</arm_group_label>
    <arm_group_label>Homozygous F508del/F508del 4-week Cohort: TEZ/IVA</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: TC-High</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: TC-Low</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: Dual TEZ</arm_group_label>
    <other_name>TEZ</other_name>
    <other_name>VX-661</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivacaftor</intervention_name>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort A:Triple Combination(TC)</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort B TC-High</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort B:TC-Low</arm_group_label>
    <arm_group_label>Homozygous F508del/F508del 4-week Cohort: TC- High</arm_group_label>
    <arm_group_label>Homozygous F508del/F508del 4-week Cohort: TEZ/IVA</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: TC-High</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: TC-Low</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: Dual IVA</arm_group_label>
    <other_name>IVA</other_name>
    <other_name>VX-770</other_name>
    <other_name>Kalydeco</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-440</intervention_name>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort A:Triple Combination(TC)</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort B TC-High</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort B:TC-Low</arm_group_label>
    <arm_group_label>Homozygous F508del/F508del 4-week Cohort: TC- High</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: TC-High</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: TC-Low</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: Dual IVA</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: Dual TEZ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matched Placebos</intervention_name>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort A: Triple Placebo</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 4-week Cohort B:TC-Low</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 4- week Cohort B: Triple Placebo</arm_group_label>
    <arm_group_label>Homozygous F508del/F508del 4-week Cohort: TC- High</arm_group_label>
    <arm_group_label>Homozygous F508del/F508del 4-week Cohort: TEZ/IVA</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: TC-Low</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: Dual IVA</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: Dual TEZ</arm_group_label>
    <arm_group_label>Heterozygous F508del/MF 12-week Cohort: Triple Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to comply with scheduled visits, treatment plan, study restrictions,
             laboratory tests, contraceptive guidelines, and other study procedures.

          -  To prevent pregnancy, female participants of childbearing potential and their male
             partners will be required to use pre-specified, highly effective methods of
             non-hormonal contraception. Male participants with female partners of childbearing
             potential will be required to use a condom.

          -  Body weight ≥35 kg.

          -  Sweat chloride value ≥60 mmol/L from test results obtained during screening.

          -  Subjects must have an eligible CFTR genotype:

               -  Heterozygous for F508del and a minimal function (MF) mutation known or predicted
                  not to be responsive to TEZ and/or IVA.

               -  Homozygous for F508del

          -  Subjects must have an FEV1 ≥40% and ≤90% of predicted normal for age, sex, and height
             at the Screening Visit

          -  Stable CF disease as judged by the investigator.

          -  Willing to remain on a stable CF medication regimen through the planned end of
             treatment or, if applicable, the Safety Follow up Visit.

        Exclusion Criteria:

          -  History of any comorbidity that, in the opinion of the investigator, might confound
             the results of the study or pose an additional risk in administering study drug to the
             subject.

          -  History of cirrhosis with portal hypertension.

          -  Risk factors for Torsade de Pointes

          -  History of hemolysis.

          -  Glucose-6-phosphate dehydrogenase (G6PD) deficiency assessed at Screening.

          -  Clinically significant abnormal laboratory values at screening

          -  An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in
             therapy for pulmonary disease within 28 days before the first dose of study drug.

          -  Lung infection with organisms associated with a more rapid decline in pulmonary status

          -  An acute illness not related to CF within 14 days before the first dose of study drug

          -  A standard digital ECG demonstrating QTc &gt;450 msec at screening.

          -  History of solid organ or hematological transplantation.

          -  History or evidence of cataract or lens opacity determined to be clinically
             significant by the ophthalmologist or optometrist based on the ophthalmologic
             examination during the Screening Period.

          -  History of alcohol or drug abuse in the past year, including but not limited to,
             cannabis, cocaine, and opiates, as deemed by the investigator.

          -  Ongoing or prior participation in an investigational drug study, with certain
             exceptions. (e.g., ongoing participation in NCT02565914)

          -  Use of commercially available CFTR modulator (e.g., Kalydeco, Orkambi) within 14 days
             before screening (applies only to the Heterozygous F508del/MF cohorts; does not apply
             to the Homozygous F508del/F508del Cohort).

          -  Pregnant or nursing females: Females of childbearing potential must have a negative
             pregnancy test at screening and Day 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Arizona Board of Regents on behalf of the University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joe Di Maggio Cystic Fibrosis &amp; Pulmonary Center</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Florida Pulmonary Group</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's CF Center of Idaho</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cystic Fibrosis Center of Chicago</name>
      <address>
        <city>Glenview</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cystic Fibrosis Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Hawthorne</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Medical Center</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Respiratory Diseases of Children and Adolescents</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC OSPARS Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Children's Specialty Clinic Sanford Research USD</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Southwestern Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of the Kings Daughters</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Hunter Hospital &amp; Hunter Medical Research Institute</name>
      <address>
        <city>New Lambton Heights</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitat Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hopsital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juliane Marie Center, Righospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mukeviszidose-Zentrum am Universtitatsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Cologne</name>
      <address>
        <city>Koeln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumologische Praxis Pasing</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d´Hebron Servicio de Broncoscopia</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Seville</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart of England NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton &amp; Harefield NHS Foundation Trust, Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2016</study_first_submitted>
  <study_first_submitted_qc>October 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2016</study_first_posted>
  <last_update_submitted>September 28, 2017</last_update_submitted>
  <last_update_submitted_qc>September 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivacaftor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

